# AgeDefy Peptide — Longevity & Cellular Health Research Peptides > AgeDefy Peptide is a reference desk for Longevity & Cellular Health research molecules — NAD+ and MOTS-c — summarized from peer-reviewed literature. A digest, not a vendor or clinic. A calm reading desk for the published science on NAD+ and MOTS-c — what each was actually studied for, in which species, and how strong the evidence really is. ## The short version AgeDefy Peptide is a reading desk, not a store. It collects what the published research literature actually says about two molecules that sit at the intersection of cellular aging science: NAD+ and MOTS-c. Both are connected to how cells manage energy as they age, and both are active areas of investigation for longevity and metabolic health — but they occupy very different positions in the evidence hierarchy. **NAD+** is not a peptide at all; it is a small coenzyme found in every cell in the body. It is one of the most-studied molecules in aging biology, with human clinical trials running into the dozens. **MOTS-c** is a true peptide — sixteen amino acids encoded within the mitochondrial genome itself — with most of its evidence still in animal models and only early human observational data. This desk does one job: it tells you, in plain language and with citations, what each molecule was tested on, in which species, and how far that evidence really reaches. It does not sell anything, does not give medical advice, and never lists a human dose. ## What are research peptides? Proteins in your body are long chains of amino acids folded into a shape that lets them do a specific job — carry oxygen, break down a sugar, send a signal. A *peptide* is a much shorter chain of the same amino acids, sometimes only a handful of links long. Because they are small and specific, peptides can act like precise keys that fit particular locks (receptors or enzymes) on cells, switching certain processes on or off. A *research peptide* is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, occasionally in early human pilots — but has **not** been approved by a regulator as a medicine. Research peptides are sold by chemical suppliers for laboratory use only, and that framing matters: it means dosing, long-term safety, and real-world effectiveness in people are usually unestablished. NAD+ occupies a different regulatory niche — it and its precursors are widely sold as dietary supplements and administered as IV wellness therapy, which is why the desk covers both the supplement evidence and the unanswered questions. ## How these two fit into longevity research NAD+ and MOTS-c approach cellular aging from different angles, which is exactly why they sit together on this desk. - [**NAD+**](/nad) is the lead. It is a dinucleotide — two nucleotide units joined by a phosphate bridge — found in every living cell, where it shuttles electrons through energy metabolism and is consumed by signaling enzymes that regulate DNA repair, gene expression, and inflammation [4]. Its tissue levels decline reliably with age, in part because a NAD-consuming ectoenzyme called CD38 rises [6]. Human clinical trials with precursors such as NMN and NR have documented consistent blood NAD+ elevation [2][5], though translation to hard longevity endpoints in humans remains an active, contested research question [1]. - [**MOTS-c**](/mots-c) is encoded inside the mitochondrial genome, which makes it unusual — most peptides and proteins are coded in the cell nucleus. Its best-characterized action is activating AMPK through the folate cycle, improving glucose handling and insulin sensitivity in skeletal muscle [10]. In aged mice it significantly enhanced physical performance, and circulating MOTS-c levels have been associated with mortality and cardiovascular risk in a human cohort [9][11]. No human efficacy trials have been completed. Together they sketch the cellular aging question from two sides: the energetics of the cell's fuel supply, and the mitochondrion's own signaling back to the rest of the cell. Use the directory to read each one, or [compare these molecules](/compare) side by side. ## A note on how this desk reads the literature AgeDefy Peptide is a cross-referenced literature digest. Each page summarizes the peer-reviewed studies for that molecule, cites them by number, and links to a single shared [references list](/references) that aggregates every source across both. Where the evidence is thin, single-lab, or preclinical, the pages say so plainly — that candor about limits is part of the record, not a footnote to it. Research findings and cited cautions are reported; nothing is recommended, prescribed, or sold. The aim is a quiet, accurate map of what is known, so you can see where the science is solid and where it is still mostly promise. --- A calm literature desk for cellular aging research — citations and context, not prescriptions and not products.